Gross sales 2016-2020, Main Producers, 2020-2021 Costs, Prospects 2021-2025

[ad_1]

DUBLIN, Dec. 31, 2021 /PRNewswire/ — The “Investigation Report on China’s Temozolomide Market 2021-2025″ report has been added to ResearchAndMarkets.com’s providing.

The gross sales worth of Temozolomide within the Chinese language market elevated yr by yr from 2016 to 2019. Because of the influence of COVID-19 on the general analysis and therapy providers of Chinese language hospitals, the gross sales worth of Temozolomide within the Chinese language market decreased to CNY793 million in 2020 and the CAGR of Temozolomide in gross sales worth from 2016 to 2020 is 9.04%.

Temozolomide is a second-generation alkylating agent. It’s an oral chemotherapeutic drug used to deal with mind cancers similar to grownup malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc. The drug was authorised to enter the Chinese language market below the commerce title TEMODAL in 2007. By 2020, Temozolomide has been included in China’s Class B medical insurance coverage. There are lots of producers within the Chinese language market in 2020, amongst which Merck Sharp & Dohme Ltd is the principle producer.

The analyst expects that with the reduction of COVID-19, the gross sales worth of Temozolomide within the Chinese language market could have a restorative development from 2021 to 2025. As well as, because the incidence of major mind most cancers will increase, different cancers may cause secondary mind most cancers.

Due to this fact, with the widespread use of digital digital merchandise and the rise within the incidence of different cancers, the incidence of mind most cancers can be rising yr by yr, the gross sales worth and gross sales quantity of Temozolomide for the therapy of mind most cancers will proceed to extend.

On the similar time, Temozolomide has the traits of simply penetrating the blood-cerebrospinal fluid barrier and delicate hostile reactions. The analyst predicts that the gross sales worth and gross sales quantity of Temozolomide within the Chinese language market could have room for improve from 2021 to 2025.

Matters Lined:

  • The influence of COVID-19 on China’s Temozolomide market
  • Gross sales worth of China’s Temozolomide 2016-2020
  • Aggressive panorama of China’s Temozolomide market
  • Costs of Temozolomide in China
  • Costs of Temozolomide in China by areas and producers
  • Evaluation on elements affecting the event of China’s Temozolomide market
  • Prospect of China’s Temozolomide market from 2021 to 2025

Key Matters Lined:

1 Related Ideas of Temozolomide
1.1 Indications for Temozolomide
1.2 Growth of Temozolomide in China
1.3 Governmental Approval of Temozolomide in China
1.4 The Affect of COVID-19 on Temozolomide gross sales in China

2 Gross sales of Temozolomide in China, 2016-2020
2.1 Gross sales Worth of Temozolomide
2.1.1 General Gross sales Worth
2.1.2 Gross sales Worth by Area
2.2 Gross sales Quantity of Temozolomide
2.2.1 General Gross sales Quantity
2.2.2 Gross sales Quantity by Area
2.3 Gross sales of Temozolomide by Dosage Kind in China, 2016-2020
2.3.1 Injection
2.3.2 Evaluation of Different Dosage Types

3 Evaluation of Main Temozolomide Producers in China in 2020
3.1 Evaluation of Market Share of Main Temozolomide Producers
3.1.1 Investigation on Market Share by Gross sales Worth
3.1.2 Investigation on Market Share by Gross sales quantity
3.2 Merck Sharp & Dohme Ltd
3.2.1 Enterprise Profile
3.2.2 Gross sales of TEMODAL (Merck Sharp & Dohme Ltd’s Temozolomide) in China
3.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Gross sales of Diqing (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.’s Temozolomide) in China
3.4 Beijing Shuanglu Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Gross sales of Jiaoning (Beijing Shuanglu Pharmaceutical Co., Ltd.’s Temozolomide) in China
3.5 Schering-Plough Canada
3.5.1 Enterprise Profile
3.5.2 Gross sales of TEMODAL (Schering-Plough Canada’s Temozolomide) in China
3.6 Jiangsu Hengrui Medication Firm Ltd.
3.6.1 Enterprise Profile
3.6.2 Gross sales of Jiangsu Hengrui Medication Firm Ltd.’s Temozolomide in China

4 Costs of Temozolomide for Totally different Producers in China, 2020-2021
4.1 Merck Sharp & Dohme Ltd (TEMODAL)
4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
4.3 Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)
4.4 Schering-Plough Canada (TEMODAL)
4.5 Jiangsu Hengrui Medication Firm Ltd.

5 Prospect of Chinese language Temozolomide drug Market, 2021-2025
5.1 Influential Elements of Chinese language Temozolomide Market Growth
5.2 Forecast on Market Dimension
5.3 Forecast on Market Pattern

Corporations Talked about

  • Merck Sharp & Dohme Ltd (TEMODAL)
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
  • Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)
  • Schering-Plough Canada (TEMODAL)
  • Jiangsu Hengrui Medication Firm Ltd.

For extra details about this report go to https://www.researchandmarkets.com/r/sheueq

Media Contact:

Analysis and Markets
Laura Wooden, Senior Supervisor
[email protected]

For E.S.T Workplace Hours Name +1-917-300-0470
For U.S./CAN Toll Free Name +1-800-526-8630
For GMT Workplace Hours Name +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outdoors U.S.): +353-1-481-1716

SOURCE Analysis and Markets

Associated Hyperlinks

http://www.researchandmarkets.com

[ad_2]

Source link

Crypto Pal

Keeping you up to date on all things crypto and the future of money.

Leave a Reply

Your email address will not be published. Required fields are marked *